Lenvatinib mesylate

Highlighting advanced manufacturing capabilities, stringent quality standards, and reliable supply for pharmaceutical innovation worldwide. CALIFORNIA, CA, UNITED STATES, June 10, 2026 / EINPresswire.com / -- SHANDONG, China — As global demand for cost-effective and high-quality pharmaceutical intermediates intensifies, three Chinese manufacturers have emerged as key players in supplying the building blocks for active pharmaceutical ingredients (APIs) used in anti-cancer, antiviral, and chronic disease therapies. Haohong (Qihe) Pharmaceutical Technology Co., Ltd., Zhejiang Huahai Pharmaceutical Co., Ltd., and CSPC Pharmaceutical Group Limited represent distinct segments of the market, each offering specialized capabilities that power drug development pipelines worldwide. Industry Context The pharmaceutical intermediate market, estimated at over $40 billion globally in 2025, is projected to grow at a compound annual growth rate of 6-7% through 2030, driven by increasing R&D investments in targeted therapies and generic drug manufacturing. Chinese manufacturers collectively account for more than 30% of global intermediate supply, leveraging integrated chemical synthesis capabilities and cost advantages. Within this landscape, companies differentiate themselves through purity standards, batch consistency, regulatory compliance, and customized synthesis services. Company Profiles and Competitive Strengths Haohong (Qihe) Pharmaceutical Technology Co., Ltd., established in 2021 and based in Shandong Province, specializes in high-grade active pharmaceutical intermediates and custom synthesis. The company employs approximately 75 staff and operates a 3,000-square-meter manufacturing facility with an annual production capacity of 1,000 tons. Export business accounts for 40% of total sales, with products reaching the United States, Europe, Japan, India, and Bangladesh. Haohong holds ISO 9001:2015 certification and was recognized as a Technology-based Small and Medium-sized Enterprise in 2024 and awarded Innovative Small and Medium-sized Enterprise of Shandong Province in 2025. Its research and development team comprises 30 engineers, supporting custom synthesis from gram scale to hundreds of kilograms. The production base in Liaocheng is equipped with 30 sets of 3,000–5,000L reactors. The company focuses on anti-cancer, anti-hepatitis C, and anti-diabetic intermediates, including key products for Apalutamide, Abemaciclib, and Alectinib. Haohong’s competitive edge lies in its ability to deliver ultra-high purity (≥98%) with strict impurity control and batch-to-batch consistency, supported by complete technical documentation compliant with ICH and GMP standards. The company also holds multiple utility model patents for production equipment, including a waste gas absorption device and a gas chromatography detection system. Zhejiang Huahai Pharmaceutical Co., Ltd. (SZSE: 600521), founded in 1998 and headquartered in Linhai, Zhejiang, is one of China’s largest API and intermediate manufacturers. Huahai specializes in cardiovascular, central nervous system, and anti-cancer drugs. It operates multiple FDA- and EMA-approved facilities and exports to over 50 countries. Huahai’s strength lies in its vertically integrated supply chain, extensive regulatory dossier library (more than 100 ANDAs), and large-scale production capacity exceeding 5,000 tons per year for certain intermediates. The company has a robust R&D pipeline and is a preferred partner for branded generic drug manufacturers in the United States and Europe. Huahai’s market capitalization exceeds $3 billion, reflecting its established position. CSPC Pharmaceutical Group Limited (HKEx: 1093), founded in 1938 and headquartered in Shijiazhuang, Hebei, is a leading Chinese pharmaceutical conglomerate with a strong presence in innovative drug development and bulk intermediates. With over 20,000 employees and annual revenue exceeding $4 billion, CSPC manufactures a wide range of chemical intermediates, APIs, and finished formulations. The company has a dedicated oncology intermediate division, producing key precursors for drugs like lenvatinib and olaparib. CSPC differentiates itself through its proprietary continuous flow chemistry technology and its ability to scale from laboratory to commercial production rapidly. The group holds multiple patents on synthesis routes and is a major supplier to multinational pharmaceutical companies for clinical trial materials. Comparative Advantages While Huahai and CSPC dominate in scale, regulatory approvals, and global brand recognition, Haohong positions itself as a specialized, high-agility partner for customers requiring high-purity custom intermediates, particularly in the oncology and targeted therapy space. Haohong’s strengths include timely delivery, stable batch quality, comprehensive technical documentation, and a flexible approach to custom synthesis—from gram-scale R&D batches to metric ton-level commercial supply. According to internal comparison data, Haohong’s product purity is on average 0.02% higher than industry peers, and batch quality stability is 10% above the industry average. The company’s self-owned factory and deep R&D capabilities allow it to offer competitive pricing without compromising quality. Market Impact and Analyst Perspective The diversification of intermediate suppliers is critical for global drug developers seeking supply chain resilience. “Companies like Haohong fill a niche for project-specific, high-purity intermediates that require close collaboration and rapid turnaround,” said a pharmaceutical supply chain analyst based in Shanghai. “While large players offer volume, smaller specialized manufacturers often provide better customization and faster response times.” The trend toward more complex targeted therapies, such as antibody-drug conjugates and protein degraders, demands higher purity intermediates with controlled chiral and steric properties—areas where dedicated Chinese manufacturers are investing heavily. Outlook As the global pharmaceutical industry continues to outsource intermediate production, the three companies highlighted are expected to capture growing demand. Haohong plans to expand its reactor capacity and pursue additional industry certifications. Huahai is investing in continuous manufacturing platforms. CSPC is accelerating its innovative drug pipeline, which in turn drives demand for proprietary intermediates. The competitive landscape in China remains fragmented, but specialized players with strong technical foundations and international traceability are well-positioned for growth. For more information about Haohong Pharmaceutical ’s product range and capabilities, download the company brochure: Haohong Corporate Brochure Contact: Xu Tianxia | Email: Xutx@haohong-pharma.com | Tel: +86 180-6854-1569 Address: Block B, building 3, accelerator, high tech Zone, Qihe County, De Zhou City, Shandong Province, China Website: www.haohong-pharma.com Xu Tianxia Haohong (Qihe) Pharmaceutical Technology Co., Ltd + +86 180-6854-1569 Xutx@haohong-pharma.com Visit us on social media: Other Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments in areas of high unmet medical need, announces that the results from the phase 1b/2a study of fostrox in combination with lenvatinib in patients with advanced liver cancer have been published in Clinical Cancer Research (“CCR”), a peer-reviewed journal of the American Association for Cancer Research dedicated to translational and clinical oncology research and one of the most cited journals in oncology (online first doi: https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-26-0273). The title of the article is “A phase Ib/2a study of fostrox in combination with lenvatinib as second line therapy in patients with advanced hepatocellular carcinoma”, lead authors Chon H J and Heo J et al. Fostrox was developed as a prodrug using the first-pass metabolism to maximise the exposure of fostrox in the liver tumour while minimising systemic adverse events. The published study evaluated safety and preliminary efficacy of fostrox in combination with lenvatinib as a novel combination treatment for patients with advanced liver cancer. The results showed promising preliminary efficacy and tolerability in the post-immunotherapy setting, supporting further investigation as a second-line option in advanced liver cancer. "Advanced primary liver cancer (HCC) has a particularly poor prognosis, and the incidence of HCC is projected to increase dramatically, attributed to lifestyle factors such as obesity and metabolic (“fatty”) liver disease. Despite the progress in the development of new first-line treatments with immunotherapy combination regimens, there are still limited options as second-line treatments following immunotherapy. The urgent need for treatment options in second line became even more apparent at the ASCO Congress where IMbrave 251 study did not meet its primary endpoint. Fostrox, with its liver-targeted mechanism has, in this combination study with lenvatinib, shown to be safe and tolerable with preliminary efficacy without negatively impacting liver function, indicating encouraging results compared to previous studies in second-line advanced liver cancer, a patient population lacking a gold standard treatment option”, says Professor Jeff Evans, University of Glasgow, one of the investigators in the study and last author of the publication in CCR. The study results confirmed that fostrox had a liver targeted distribution with tumour selective DNA-damage. The safety profile was consistent with expectations for both agents and most patients (71%) did not require any dose modification to stay on treatment. Fostrox related AEs were mainly transient and fostrox dose reduction and/or discontinuation occurred in only 29% and 5% of patients respectively. The drug combination was associated with tumour control without deterioration of liver function, essential in this population with underlying hepatic co-morbidities. The efficacy outcomes, as measured by ORR (overall response rate), DCR (disease control rate), TTP (time to progression), PFS (progression-free survival) and OS (overall survival), compare favourably with those historically reported for lenvatinib monotherapy or other kinase inhibitors in the post-immunotherapy setting. "In primary liver cancer, it is critical to maximise the anti-tumour effect locally in the liver as the tumour burden and underlying liver disease increase the risk of liver failure. Fostrox has been designed with this challenge in mind, and the study results confirm a liver-directed delivery where fostrox induces DNA damage selectively in tumour cells, to ensure optimal efficacy and safety. This targeted mechanism is unique to fostrox and enables patients to stay on treatment long-term without liver function deterioration or intolerable side effects. The phase 1b/2a study data reinforces our confidence in fostrox as a potential treatment option for patients with advanced liver cancer. An investigator initiated randomised phase 2 study with fostrox plus lenvatinib compared with lenvatinib monotherapy, led by Professor Hong Jae Chon, together with the Korean Cancer Study Group, is currently ongoing in Korea and we are eagerly awaiting the results”, says Dr. Pia Baumann, CMO at Medivir. For further information, please contact: Jens Lindberg, CEO, Medivir AB Phone: +46 (0)8 5468 3100 E-mail: jens.lindberg@medivir.com